TY - JOUR
T1 - Development of an Innovative Dual Construct for Targeted Drug Delivery in the Oral Cavity
AU - Mazzinelli, Elena
AU - Favuzzi, Ilaria
AU - Messina, Marianna
AU - Fratocchi, Giorgia
AU - Vincenzoni Dottoressa, Federica
AU - Santo Stefano, Eleonora
AU - Cecconi, Francesco
AU - Lajolo, Carlo
AU - Basco, Alessia
AU - Castagnola, Raffaella
AU - Cordaro, Massimo
AU - Scilla, Francesco
AU - Papa, Valerio
AU - Arcovito, Alessandro
AU - Cacciotti, Ilaria
AU - Nocca, Giuseppina
PY - 2025
Y1 - 2025
N2 - Background: Oral lichen planus (OLP) is a chronic autoimmune disease of the oral mucosa, classified among potentially malignant oral disorders (OPMDs). It is characterized by keratinocyte apoptosis and persistent inflammation. Standard treatments involve topical corticosteroids administered via mouthwashes, gels, or ointments, but these require frequent application, have limited retention, and may cause side effects. To address these limitations, this study aimed to develop an innovative dexamethasone delivery system targeting the oral cavity, based on poly(lactic acid) (PLA) fibers coated with chitosan (CS) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Methods: CS-coated PLA fibers were characterized for their mucoadhesive and cytocompatibility properties, while PLGA nanoparticles were analyzed for size, shape, encapsulation efficiency, cellular uptake, drug release efficiency, and cytocompatibility. Results: Both polymers demonstrated cytocompatibility, and chitosan-coated PLA fibers exhibited mucoadhesive properties. PLGA nanoparticles were effectively internalized by the cells and successfully released the drug into the cytoplasm. The combination of CS-coated PLA fibers and PLGA nanoparticles provided dual benefits: mucoadhesion and efficient cellular uptake, even under conditions simulating salivation. Conclusions: These findings highlight the potential of the proposed system to improve mucoadhesive drug delivery. Further optimization is needed to enhance patient compliance and therapeutic efficacy.
AB - Background: Oral lichen planus (OLP) is a chronic autoimmune disease of the oral mucosa, classified among potentially malignant oral disorders (OPMDs). It is characterized by keratinocyte apoptosis and persistent inflammation. Standard treatments involve topical corticosteroids administered via mouthwashes, gels, or ointments, but these require frequent application, have limited retention, and may cause side effects. To address these limitations, this study aimed to develop an innovative dexamethasone delivery system targeting the oral cavity, based on poly(lactic acid) (PLA) fibers coated with chitosan (CS) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Methods: CS-coated PLA fibers were characterized for their mucoadhesive and cytocompatibility properties, while PLGA nanoparticles were analyzed for size, shape, encapsulation efficiency, cellular uptake, drug release efficiency, and cytocompatibility. Results: Both polymers demonstrated cytocompatibility, and chitosan-coated PLA fibers exhibited mucoadhesive properties. PLGA nanoparticles were effectively internalized by the cells and successfully released the drug into the cytoplasm. The combination of CS-coated PLA fibers and PLGA nanoparticles provided dual benefits: mucoadhesion and efficient cellular uptake, even under conditions simulating salivation. Conclusions: These findings highlight the potential of the proposed system to improve mucoadhesive drug delivery. Further optimization is needed to enhance patient compliance and therapeutic efficacy.
KW - chitosan coating
KW - dexamethasone
KW - drug delivery
KW - poly(lactic-co-glycolic acid) nanoparticles
KW - oral cavity
KW - poly(lactic acid) fibers
KW - mucoadhesivity
KW - chitosan coating
KW - dexamethasone
KW - drug delivery
KW - poly(lactic-co-glycolic acid) nanoparticles
KW - oral cavity
KW - poly(lactic acid) fibers
KW - mucoadhesivity
UR - http://hdl.handle.net/10807/311047
U2 - 10.3390/pharmaceutics17020272
DO - 10.3390/pharmaceutics17020272
M3 - Article
SN - 1999-4923
VL - 17
SP - N/A-N/A
JO - Pharmaceutics
JF - Pharmaceutics
ER -